Article - 14 January 2026
Improving Outcomes for Patients with Solid Tumors
OmniSeq® INSIGHT delivers a comprehensive and user-friendly report that offers clinical guidance for more precise and targeted treatment options and clinical trials tailored to your patients within 7-10 days.
Profiling Empowers
You to Make Better Decisions
From a single tumor biopsy, analyzed by advanced next generation sequencing (NGS) technology, OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report.
We deliver both DNA and RNA fusion sequencing results for 96% of sequenced cases, reflecting our commitment to quality control and robust workflow.
Genomic profiling
- 523 Gene NGS Panel
- Homologous recombination deficiency (HRD)
- DNA and RNA sequencing
- Single nucleotide variants (SNVs) – insertions/deletions (indels), copy number alterations (CNAs) and fusions
- Interrogation of full coding regions
- HLA genotyping
Immunotherapy biomarkers
- PD-L1 by immunohistochemistry (IHC)
- Microsatellite instability (MSI) and tumor mutational burden (TMB)
Labcorp Perspectives Oncology (Episode 5): Redefining ovarian cancer care with biomarkers
Why Choose OmniSeq INSIGHT?
1
Single Tumor Biopsy
A single tissue sample provides complete insight into the tumor and its microenvironment.
2
Pan-Cancer Testing
The report provides comprehensive genomic for all solid tumors.
3
Treatment Options
A summary of FDA-approved therapies, immunotherapies and eligible clinical trials tailored to your patient’s solid tumor.
Identify Approved Drug Candidates
- Comprehensive Genomics
- Detects all four main classes of genomic alterations
- Fusions / splice variants using RNA-Seq hybrid capture
- Coverage of clinical practice guideline-recommended biomarkers across solid tumor types
- Homologous recombination deficiency (HRD) available for patients with ovarian, fallopian tube, and primary peritoneal cancers
Immunotherapy Eligibility
- Comprehensive Immune Profiling
- MSI & TMB profiling
- PD-L1 by IHC
Eligible Clinical Trials
- List of patient-eligible clinical trials within 200 miles of patient’s physical address1
- Testing for biomarkers with clinical trial associations
Patient Reports: Concise, Comprehensive & Actionable
Comprehensive Quick-Read Results
Gain actionable insights at a glance with:
- Clinically significant results
- Pertinent negative genomic variants
- A therapy considerations summary
- Flagged potential cancer-associated hereditary variants
THERAPY CONSIDERATIONS
Start to formulate a plan with:
- Full-label indications
- Treatment setting and approval status
- Guideline evidence
- Emerging clinical benefits
MARKER DETAILS
See the bigger picture with:
- Full biomarker details
- Gene, variant and prevalence information
Clinical Trial Options
Expand your patient’s options with:
- Number of trial matches per marker
- Clinical significance for matched trials
Analytical results:
- Genomic variants results section by variant type (SNV/indel, fusion, copy gain/loss)
- Clinically significant variants with reference to details pages
- Sections always show, even if results are null
- VUS in appendix
Reporting of HLA Class I
Clear description of pertinent negative genomic variants
Flagged potential cancer-associated hereditary variants
Test description
Easy to find marker list located on last page of the report
Clear explanations of testing issues, if any
Explanation of clinical significance
Guideline info
Treatment settings and approval status
Multi-marker associations
Number of trial matches per marker
The Oncology Dashboard
A dynamic online report for OmniSeq® INSIGHT to power better decisions
View patient-centric Labcorp data and insights where it matters most—right at the point of care. The Oncology Dashboard, as a part of Labcorp Diagnostic AssistantTM, provides clinically actionable information, such as biomarker data and therapeutic recommendations, along with evidence-based guidelines and supporting references. The Oncology Dashboard is accessible through a provider’s electronic health record (EHR) and Labcorp LinkTM.
A dynamic report to support clinical decision-making.
Easy access to Labcorp data to support oncology care
View OmniSeq INSIGHT reports along with core clinical test results for each patient.
Enhanced oncology reports
Precision oncology reports are enriched with interactive digital results. Get related clinical trial information and access to PubMed® articles with supporting evidence.
Dashboard of clinical report
| Sample requirements (include pathology report) |
|---|
Formalin fixed paraffin embedded (FFPE) tissue
**Do not submit decalcified specimens, cytology smears or samples from hematologic malignancies** |
| FFPE block (preferred) or 15 unbaked, positively charged, unstained slides cut a 5 µm plus one H&E |
| Turnaround time: 7-10 days from sample receipt to report |
See test menu for additional information
OmniSeq Corporate & Lab Certifications
Labcorp Broad National Coverage
- In-network with most major health plans
- 1,600+ contractual relationships with plans, payers and other healthcare organizations
More About OmniSeq INSIGHT
Article - 17 November 2025
Driving precision oncology development: Integrated biomarker testing solutions that deliver impact
Poster - 7 April 2024
Landscape of TIGIT and PD-L1 co-expression in solid tumors
Peer-Reviewed Publication - 19 March 2024
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
To submit a complaint related to this offering, please complete this form.
References
1. OmniSeq Knowledgebase - trial radius may be modified for select locations.